Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Inclusion Criteria

• •1.Age older than 16 years old,gender and race no limited.
• •2.Pathological diagnosis of CD19 express positive recurrent or refractory B lymphoma, satisfy any of the following a diagnosis of recurrent or refractory lymphoma: (1) According to the standard solution standardization more than four courses of treatment, tumor size \< 50% or progression;(2) According to the standard solution treatment of complete remission, after recurrence again with the original plan or the national expert consensus recommended second-line cannot again get to complete remission (3) Relapse after hematopoietic stem cell transplantation.
• •3.Patients into the group needs lesions to be available for testing or evaluating disease.
• •4.ECOG score reaches 0 to 1 points.
• •5.Patients into the group of White Blood Cell counts in peripheral blood acuity≥ 1.0 x10\^9 / L.
• •6.Estimated survival times \> 90 days.
• •7.Patients have self-knowledge ability, can sign the informed consent form.